Our top pick for
Quotient Limited is a diagnostics & research business based in the US. Quotient shares (QTNT) are listed on the NASDAQ and all prices are listed in US Dollars. Quotient employs 420 staff and has a trailing 12-month revenue of around USD$41.6 million.
|Latest market close||USD$5.21|
|52-week range||USD$2.395 - USD$9.65|
|50-day moving average||USD$6.4791|
|200-day moving average||USD$6.3333|
|Wall St. target price||USD$12.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.731|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-6.63%|
|1 month (2020-12-16)||-25.25%|
|3 months (2020-10-16)||5.25%|
|6 months (2020-07-16)||-36.54%|
|1 year (2020-01-16)||-40.11%|
|2 years (2019-01-16)||-30.81%|
|3 years (2018-01-16)||24.34%|
|5 years (2016-01-15)||13.98|
|Revenue TTM||USD$41.6 million|
|Gross profit TTM||USD$14.9 million|
|Return on assets TTM||-20.78%|
|Return on equity TTM||0%|
|Market capitalisation||USD$553.6 million|
TTM: trailing 12 months
There are currently 4.9 million Quotient shares held short by investors – that's known as Quotient's "short interest". This figure is 1.5% down from 5.0 million last month.
There are a few different ways that this level of interest in shorting Quotient shares can be evaluated.
Quotient's "short interest ratio" (SIR) is the quantity of Quotient shares currently shorted divided by the average quantity of Quotient shares traded daily (recently around 830242.80879865). Quotient's SIR currently stands at 5.91. In other words for every 100,000 Quotient shares traded daily on the market, roughly 5910 shares are currently held short.
However Quotient's short interest can also be evaluated against the total number of Quotient shares, or, against the total number of tradable Quotient shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Quotient's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Quotient shares in existence, roughly 50 shares are currently held short) or 0.0571% of the tradable shares (for every 100,000 tradable Quotient shares, roughly 57 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Quotient.
Find out more about how you can short Quotient stock.
We're not expecting Quotient to pay a dividend over the next 12 months.
Over the last 12 months, Quotient's shares have ranged in value from as little as $2.395 up to $9.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Quotient's is 2.6142. This would suggest that Quotient's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company is also developing microarray-based SARS-CoV-2 antibody test for use on the MosaiQ platform for COVID-19. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.